Jefferies analyst Vanessa Jeffriess has maintained their bullish stance on VCT stock, giving a Buy rating on February 4.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Vanessa Jeffriess’s rating is based on several compelling factors influencing Victrex’s market position. The company has demonstrated a significant year-over-year volume increase of 20% in the first quarter of 2025, which is a strong indicator of growth potential. Despite ongoing challenges in the medical sector, the forecast for fiscal year 2025 remains stable, with January showing promising results.
Jeffriess identifies Victrex as a standout within the cyclical recovery domain, highlighting its operating leverage fueled by rising demands in Sustainable Solutions and the potential for medical sector recovery. The valuation of the company suggests an appealing margin profile, positioning Victrex as an attractive option for potential buybacks. These elements contribute to the Buy rating, underscoring the firm’s upside potential within the current market landscape.
In another report released on February 4, Morgan Stanley also initiated coverage with a Buy rating on the stock with a £13.00 price target.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.